Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Mullen

Critical Care Medicine Greenville, SC Medical Doctor

NPI 1447358478 CMS profile 64945

3 Saint Francis Dr, Suite 300, Greenville, SC 29601

Open in the dashboard

General payments

$5,209

273 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Mullen of Greenville, SC is reported in the CMS Open Payments database as having received $5,209 across 273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $485 11
2024 General $102 6
2023 General $599 34
2022 General $976 44
2021 General $841 52
2020 General $607 39
2019 General $1,599 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Mullen
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Charles Mullen were reported at $485. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Charles Mullen Critical Care Medicine median Middle half National median
2019 $1,599 $149 $51–$535 $163
2020 $607 $110 $30–$325 $114
2021 $841 $125 $34–$403 $132
2022 $976 $157 $49–$582 $149
2023 $599 $162 $56–$621 $160
2024 $102 $168 $53–$634 $164
2025 $485 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $529 41 payments
  2. AstraZeneca Pharmaceuticals LP $516 27 payments
  3. Electromed, Inc. $490 34 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $459 20 payments
  5. Insmed, Inc. $303 18 payments
  6. Philips Electronics North America Corporation $296 15 payments
  7. Regeneron Healthcare Solutions, Inc. $289 4 payments
  8. United Therapeutics Corporation $261 6 payments
  9. Genzyme Corporation $254 9 payments
  10. Genentech USA, Inc. $235 7 payments
  11. Other $1,578 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,108 270 payments
  2. Education $101 3 payments
Products named General payments · program years 2019–2025
  1. Arikayce $303 18 payments
  2. DUPIXENT Inflammation And Immunology $289 4 payments
  3. SMARTVEST Hfcwo $288 19 payments
  4. TRELEGY ELLIPTA $261 19 payments
  5. BREZTRI $223 8 payments
  6. DUPIXENT Immunology $211 6 payments
  7. OFEV $209 9 payments
  8. SMARTVEST Hfcwo $202 15 payments
  9. Prolastin-C Liquid $176 11 payments
  10. (8874) inCourage $159 7 payments
  11. Other $2,873 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,370

Median for Pulmonary Disease: 936

Drug cost

$1,007,059

Median for Pulmonary Disease: $487,987

Branded share of claims

78%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 40 $517,309
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 382 $292,571
Breo Ellipta Fluticasone/Vilanterol Brand 106 $50,195
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 53 $49,467
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 27 $19,815
Ambrisentan Generic 12 $14,925
Spiriva Respimat Tiotropium Bromide Brand 18 $13,235
Symbicort Budesonide/Formoterol Fumarate Brand 32 $10,338
Albuterol Sulfate Hfa Albuterol Sulfate Brand 274 $8,961
Advair Hfa Fluticasone Propion/Salmeterol Brand 14 $7,870

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$49,662

Medicare's payments for the services billed

Medicare patients

399

Average age 76

Services billed

1,042

225 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 57%
Arthritis 56%
Ischemic heart disease 45%
Heart failure 41%
Chronic kidney disease 41%
Depression 40%
Diabetes 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record